With the rapid development of detection methods, next-generation sequencing (NGS) technology as a new technology, some novel epidermal growth factor receptor (EGFR) gene fusions comprising the EGFR linked to various fusion partners, most commonly RAD51, are detected in the non-small cell lung cancer (NSCLC). We described a case of an unreported kinesin family member 5B (KIF5B)-EGFR in NSCLC and the efficacy of EGFR tyrosine kinase inhibitors (TKIs) to this specific fusion. Considering this rare EGFR fusion and remarkable response to EGFR-TKI, we should realize the importance of these rare EGFR fusions, the advances in diagnostic techniques and personalized care for lung cancer patients.
CITATION STYLE
Xu, H., & Shao, C. (2020). KIF5B-EGFR fusion: A novel EGFR mutation in lung adenocarcinoma. OncoTargets and Therapy, 13, 8317–8321. https://doi.org/10.2147/OTT.S263994
Mendeley helps you to discover research relevant for your work.